Palisade Bio Selected for Poster Presentation at the 2025 Crohn’s & Colitis Congress

GlobeNewswire

01-29

Carlsbad, CA, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced that its abstract has been accepted for poster presentation at the Crohn’s & Colitis Congress being held February 6-8, 2025 in San Francisco, CA.

Details of the poster presentation are as follows:

Session: Poster and Exhibition Hall Reception
Poster Title: PALI-2108, a Colon-Specific PDE4B Inhibitor Prodrug is Activated in the Colon and Reduces Ulcerative Colitis Symptoms in an Acute Colitis DSS Mouse Model
Session Dates and Times: February 7, 2025 from 5:00 PM to 6:30 PM PST
Presentation Location: Level 1 – Exhibition Hall – Moscone West

For more information about the congress, please visit crohnscolitiscongress.org.

About Palisade Bio

Palisade Bio is a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The Company believes that by using a targeted approach with its novel therapeutics it will transform the treatment landscape. For more information, please go to www.palisadebio.com.

Investor Relations Contact
JTC Team, LLC
Jenene Thomas
908-824-0775
PALI@jtcir.com

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2507636905"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2507636905\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2507636905?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-29 21:45","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2507636905","market":"us","top_or_hot":-1,"title":"Palisade Bio Selected for Poster Presentation at the 2025 Crohn’s & Colitis Congress","media":"GlobeNewswire","content":"<html><body><img hspace=\"5\" src=\"https://s1.yimg.com/uu/api/res/1.2/_W8n5W.NPkwb8XBlMC.shg--/cT03NTthcHBpZD15dmlkZW9mZWVkczs-/https://media.zenfs.com/en/globenewswire.com/2a3a6d9c80425bf813c98abfe355e747\" title=\"logo.png\" vspace=\"5\"/>\n<p><strong>Carlsbad, CA, Jan. 29, 2025 (GLOBE NEWSWIRE) -- </strong><u>Palisade Bio, Inc</u>. (Nasdaq: PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced that its abstract has been accepted for poster presentation at the <u>Crohn’s &amp; Colitis Congress</u> being held February 6-8, 2025 in San Francisco, CA.</p>\n<p>Details of the poster presentation are as follows:</p>\n<p><strong>Session:</strong> Poster and Exhibition Hall Reception<br/><strong>Poster Title:</strong> <em>PALI-2108, a Colon-Specific PDE4B Inhibitor Prodrug is Activated in the Colon and Reduces Ulcerative Colitis Symptoms in an Acute Colitis DSS Mouse Model</em> <br/><strong>Session Dates and Times</strong>: February 7, 2025 from 5:00 PM to 6:30 PM PST<br/><strong>Presentation Location:</strong> Level 1 – Exhibition Hall – Moscone West<br/><br/><br/></p>\n<p>For more information about the congress, please visit <u>crohnscolitiscongress.org</u>.</p>\n<p><strong>About Palisade Bio </strong></p>\n<p>Palisade Bio is a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The Company believes that by using a targeted approach with its novel therapeutics it will transform the treatment landscape. For more information, please go to <u>www.palisadebio.com</u><u>.</u></p>\n<p><strong>Investor Relations Contact</strong><br/>JTC Team, LLC<br/>Jenene Thomas <br/>908-824-0775<br/><u>PALI@jtcir.com</u><br/><br/><br/><br/></p>\n<br/></body></html>","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Palisade Bio Selected for Poster Presentation at the 2025 Crohn’s & Colitis Congress</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPalisade Bio Selected for Poster Presentation at the 2025 Crohn’s & Colitis Congress\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">GlobeNewswire</strong><span class=\"h-time small\">2025-01-29 21:45</span>\n</p>\n</h4>\n</header>\n<article>\n<html><body><img hspace=\"5\" src=\"https://s1.yimg.com/uu/api/res/1.2/_W8n5W.NPkwb8XBlMC.shg--/cT03NTthcHBpZD15dmlkZW9mZWVkczs-/https://media.zenfs.com/en/globenewswire.com/2a3a6d9c80425bf813c98abfe355e747\" title=\"logo.png\" vspace=\"5\"/>\n<p><strong>Carlsbad, CA, Jan. 29, 2025 (GLOBE NEWSWIRE) -- </strong><u>Palisade Bio, Inc</u>. (Nasdaq: PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced that its abstract has been accepted for poster presentation at the <u>Crohn’s &amp; Colitis Congress</u> being held February 6-8, 2025 in San Francisco, CA.</p>\n<p>Details of the poster presentation are as follows:</p>\n<p><strong>Session:</strong> Poster and Exhibition Hall Reception<br/><strong>Poster Title:</strong> <em>PALI-2108, a Colon-Specific PDE4B Inhibitor Prodrug is Activated in the Colon and Reduces Ulcerative Colitis Symptoms in an Acute Colitis DSS Mouse Model</em> <br/><strong>Session Dates and Times</strong>: February 7, 2025 from 5:00 PM to 6:30 PM PST<br/><strong>Presentation Location:</strong> Level 1 – Exhibition Hall – Moscone West<br/><br/><br/></p>\n<p>For more information about the congress, please visit <u>crohnscolitiscongress.org</u>.</p>\n<p><strong>About Palisade Bio </strong></p>\n<p>Palisade Bio is a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The Company believes that by using a targeted approach with its novel therapeutics it will transform the treatment landscape. For more information, please go to <u>www.palisadebio.com</u><u>.</u></p>\n<p><strong>Investor Relations Contact</strong><br/>JTC Team, LLC<br/>Jenene Thomas <br/>908-824-0775<br/><u>PALI@jtcir.com</u><br/><br/><br/><br/></p>\n<br/></body></html>\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"https://finance.yahoo.com/news/palisade-bio-selected-poster-presentation-134500430.html\">GlobeNewswire</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://finance.yahoo.com/news/palisade-bio-selected-poster-presentation-134500430.html","article_id":"2507636905","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2507636905","pubTimestamp":1738158300,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Carlsbad,CA, Jan. 29, 2025  -- Palisade Bio, Inc. , a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced that its abstract has been accepted for poster presentation at the Crohn’s & Colitis Congress being held February 6-8, 2025 in San Francisco, CA.Details of the poster presentation are as follows:. Session: Poster and Exhibition Hall ReceptionPoster Title: PALI-2108, a Colon-Specific PDE4B Inhibitor Prodrug is Activated in the Colon and Reduces Ulcerative Colitis Symptoms in an Acute Colitis DSS Mouse Model Session Dates and Times: February 7, 2025 from 5:00 PM to 6:30 PM PSTPresentation Location: Level 1 – Exhibition Hall – Moscone West","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","PALI":"Palisade Bio Inc.","BK4007":"制药"},"translate_title":"Palisade Bio入选2025年克罗恩病和结肠炎大会海报展示","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PALI":0.9},"content_text":"Carlsbad, CA, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced that its abstract has been accepted for poster presentation at the Crohn’s & Colitis Congress being held February 6-8, 2025 in San Francisco, CA.\nDetails of the poster presentation are as follows:\nSession: Poster and Exhibition Hall ReceptionPoster Title: PALI-2108, a Colon-Specific PDE4B Inhibitor Prodrug is Activated in the Colon and Reduces Ulcerative Colitis Symptoms in an Acute Colitis DSS Mouse Model Session Dates and Times: February 7, 2025 from 5:00 PM to 6:30 PM PSTPresentation Location: Level 1 – Exhibition Hall – Moscone West\nFor more information about the congress, please visit crohnscolitiscongress.org.\nAbout Palisade Bio \nPalisade Bio is a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The Company believes that by using a targeted approach with its novel therapeutics it will transform the treatment landscape. For more information, please go to www.palisadebio.com.\nInvestor Relations ContactJTC Team, LLCJenene Thomas 908-824-0775PALI@jtcir.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1}}}